(Q39975996)

16 September 2017

title

RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo (English)

1 reference

16 September 2017

A Bessard

1

1 reference

16 September 2017

C Frémin

2

1 reference

16 September 2017

F Ezan

3

1 reference

16 September 2017

A Fautrel

4

1 reference

16 September 2017

L Gailhouste

5

1 reference

16 September 2017

G Baffet

6

1 reference

16 September 2017

language of work or name

English

0 references

publication date

2 June 2008

1 reference

16 September 2017

1 reference

16 September 2017

volume

27

1 reference

16 September 2017

issue

40

1 reference

16 September 2017

page(s)

5315-5325

1 reference

Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice.

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Distinct patterns of cyclin D1 regulation in models of liver regeneration and human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Protein kinases as drug targets in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Progress towards in vivo use of siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

RNA interference in mammalian cells by chemically-modified RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

No induction of anti-viral responses in human cell lines HeLa and MCF-7 when transfecting with siRNA or siLNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Specificity and mechanism of action of some commonly used protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

A synthetic inhibitor of the mitogen-activated protein kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Analysis of gene function in somatic mammalian cells using small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

The role of erk1 and erk2 in multiple stages of T cell development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

ERK2 but not ERK1 plays a key role in hepatocyte replication: an RNAi-mediated ERK2 knockdown approach in wild-type and ERK1 null hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

The Ras-Raf-MEK-ERK pathway in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

RNA interference: from gene silencing to gene-specific therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

The MAP kinase pathway is required for entry into mitosis and cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

“Spontaneous” neoplastic transformation in vitro of epithelial cell strains of rat liver: Cytology, growth and enzymatic activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Mechanism in the sequential control of cell morphology and S phase entry by epidermal growth factor involves distinct MEK/ERK activations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Extracellular signal-regulated protein kinase 2 is required for efficient generation of B cells bearing antigen-specific immunoglobulin G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Increased MAPK expression and activity in primary human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Mechanisms of drug inhibition of signalling molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Biochemical characteristics of caspases-3, -6, -7, and -8

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

The mitogen-activated protein kinase kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G(1) phase progression in proliferating hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

In vitro and in vivo metabolism of the anti-cancer agent CI-1040, a MEK inhibitor, in rat, monkey, and human

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Clinical experience of MEK inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

Growth factor dependence of progression through G1 and S phases of adult rat hepatocytes in vitro. Evidence of a mitogen restriction point in mid-late G1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.163

31 March 2020

Identifiers

DOI

10.1038/ONC.2008.163

1 reference

16 September 2017

1 reference